2013 Fiscal Year Final Research Report
Therapeutic potential of LDL apheresis including activation of receptor-interacting molecule in the management of peripheral artery disease
Project/Area Number |
24890189
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Single-year Grants |
Research Field |
Circulatory organs internal medicine
|
Research Institution | Yokohama City University |
Principal Investigator |
IKEYA Yuko 横浜市立大学, 附属病院, 指導診療医 (60453049)
|
Project Period (FY) |
2012-08-31 – 2014-03-31
|
Keywords | シグナル伝達 / 脂質 / 循環器・高血圧 / 生体分子 / トランスレーショナルリサーチ |
Research Abstract |
Cardiovascular disease (CVD) is a major cause of death in patients with chronic kidney disease (CKD). Patients with CKD are reported to have a significant greater risk of CVD-associated mortality than that of the general population. Low-density lipoprotein (LDL) apheresis is a potentially valuable treatment applied to conventional therapy-resistant hypercholesterolemic patients with coronary artery disease and peripheral artery disease (PAD). Although previous and recent studies have suggested that LDL apheresis exerts beneficial effects on the peripheral circulation in dialysis patients suf- fering from PAD, probably through a reduction of not only serum lipids but also of inflammatory or coagulatory factors and oxidative stress, the precise molecular mechanisms underlying the long-term effects of LDL apheresis on the improvement of the peripheral circulation remains unclear and warrants further investigation, including a possible role of Ang II receptor-interacting molecule, ATRAP.
|
-
[Journal Article] Upstream stimulatory factors 1 and 2 mediate the transcription of angiotensin II binding and inhibitory protein2013
Author(s)
Matsuda M, Tamura K, Wakui H, Maeda A, Ohsawa M, Kanaoka T, Azushima K, Uneda K, Haku S, Tsurumi-Ikeya Y, Toya Y, Maeshima Y, Yamashita A, Umemura S
-
Journal Title
J Biol Chem
Volume: 288
Pages: 19238-19249
DOI
Peer Reviewed
-
[Journal Article] What can we expect from the binding characteristics of azilsartan, a newly available angiotensin II blocker, in hypertension?2013
Author(s)
Tamura K, Ohsawa M, Kanaoka T, Maeda A, Azushima K, Uneda K, Wakui H, Azuma K, Tsurumi-Ikeya Y, Umemura S
-
Journal Title
Hypertens Res
Volume: 36
Pages: 107-108
DOI
Peer Reviewed
-
[Journal Article] Therapeutic potential of low-density lipoprotein apheresis in the management of peripheral artery disease in patients with chronic kidney disease2013
Author(s)
Tamura K, Tsurumi-Ikeya Y, Wakui H, Maeda A, Ohsawa M, Azushima K, Kanaoka T, Uneda K, Haku S, Azuma K, Mitsuhashi H, Tamura N, Toya Y, Tokita Y, Kokuho T, Umemura S
-
Journal Title
Ther Apher Dial
Volume: 17
Pages: 185-192
DOI
Peer Reviewed
-
[Journal Article] Enhanced Ang receptor-associated protein in renal tubule suppresses Ang-dependent hypertension2013
Author(s)
Wakui H, Tamura K, Masuda S, Tsurumi-Ikeya Y, Fujita M, Maeda A, Ohsawa M, Azushima K, Uneda K, Matsuda M, Kitamura K, Uchida S, Toya Y, Kobori H, Nagahama K, Yamashita A, Umemura S
-
Journal Title
Hypertension
Volume: 61
Pages: 1203-1210
DOI
Peer Reviewed
-
[Journal Article] The physiology and pathophysiology of a novel angiotensin receptor-binding protein ATRAP/Agtrap2013
Author(s)
Tamura K, Wakui H, Maeda A, Dejima T, Ohsawa M, Azushima K, Kanaoka T, Haku S, Uneda K, Masuda S, Azuma K, Shigenaga A, Koide Y, Tsurumi-Ikeya Y, Matsuda M, Toya Y, Tokita Y, Yamashita A, Umemura S
-
Journal Title
Curr Pharm Des
Volume: 19
Pages: 3043-3048
DOI
Peer Reviewed
-
[Journal Article] Addition of aliskiren to Angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease2013
Author(s)
Ohsawa M, Tamura K, Kanaoka T, Wakui H, Maeda A, Dejima T, Azushima K, Uneda K, Kobayashi R, Tsurumi-Ikeya Y, Toya Y, Fujikawa T, Umemura S
-
Journal Title
Int J Mol Sci
Volume: 14
Pages: 15361-15375
DOI
Peer Reviewed
-
[Journal Article] Umemura S.L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease2013
Author(s)
Kanaoka T, Tamura K, Wakui H, Ohsawa M, Azushima K, Uneda K, Kobayashi R, Fujikawa T, Tsurumi-Ikeya Y, Maeda A, Yanagi M, Toya Y
-
Journal Title
Int J Mol Sci
Volume: 14
Pages: 16866-16881
DOI
Peer Reviewed
-
-
[Journal Article] Genetic deletion of the angiotensin II type 1 receptor-associated protein enhances renal sodium reabsorption and exacerbates angiotensin II-mediated hypertension
Author(s)
Ohsawa M, Tamura K, Wakui H, Maeda A, Dejima T, Kanaoka T, Azushima K, Uneda K, Tsurumi-Ikeya Y, Kobayashi R, Matsuda M, Uchida S, Toya Y, Kobori H, Nishiyama A, Yamashita A, Ishikawa Y, Umemura S
-
Journal Title
Kidney Int
Volume: (in press)
DOI
Peer Reviewed
-
[Journal Article] Effects of the angiotensin receptor blocker olmesartan on adipocyte hypertrophy and function in mice with metabolic disorders
Author(s)
Maeda A, Tamura K, Wakui H, Ohsawa M, Azushima K, Uneda K, Kanaoka T, Kobayashi R, Ohki K, Matsuda M, Tsurumi-Ikeya Y, Yamashita A, Tokita Y, Umemura S
-
Journal Title
BioMed Res Int
Volume: (in press)
DOI
Peer Reviewed
-